Volume 30, Number 4—April 2024
Research Letter
Opportunistic Elizabethkingia miricola Infections in Intensive Care Unit, Spain
Table
Characteristics of case-patients in an outbreak opportunistic Elizabethkingia miricola infections in an intensive care unit, Spain*
Age, y/sex | Isolation sample |
ICU stay, d | Diagnosis† | Diagnosis date, 2021 | Death | Reason for admission | Antimicrobial drug resistance‡ |
---|---|---|---|---|---|---|---|
66/M |
BAS |
40 |
Isolation |
Mar 17 |
N |
COVID-19 |
Carbapenems, ceftazidime, cefepime, aztreonam |
70/M |
BAS |
63 |
Isolation |
Mar 19 |
N |
COVID-19 |
Carbapenems, ceftazidime, cefepime, aztreonam |
46/F |
BAS |
12 |
Isolation |
Mar 27 |
Y |
Carcinosis |
Carbapenems, ceftazidime, cefepime, aztreonam, aminoglycosides |
64/M |
BAS |
61 |
Tracheobronchitis |
Apr 22 |
N |
COVID-19 |
Carbapenems, ceftazidime, cefepime, aztreonam, piperacillin/tazobactam |
57/F |
BAS, catheter |
20 |
Bacteriemia |
Apr 27 |
Y |
COVID-19 |
Carbapenems, ceftazidime, cefepime, aztreonam, piperacillin/tazobactam, aminoglycosides, trimethoprim/ sulfamethoxazole |
50/M |
BAS |
58 |
Tracheobronchitis |
May 19 |
Y |
COVID-19 |
Carbapenems, ceftazidime, amikacin |
52/M |
BAS |
37 |
Tracheobronchitis |
May 20 |
N |
COVID-19 |
Carbapenems, ceftazidime, amikacin |
56/M |
BAS |
43 |
Ventilator-associated pneumonia |
May 22 |
Y |
COVID-19 |
Amikacin |
58/F |
BAS |
80 |
Tracheobronchitis |
May 29 |
N |
COVID-19 |
Amikacin |
58/M |
BAS |
30 |
Isolation |
Jul 7 |
Y |
Fever |
Piperacillin/tazobactam, linezolid |
37/F |
BAS |
51 |
Isolation |
Aug 20 |
Y |
COVID-19 |
Piperacillin/tazobactam, linezolid |
32/M |
BAS |
93 |
Tracheobronchitis |
Sep 18 |
Y |
COVID-19 |
Piperacillin/tazobactam, linezolid |
74/M |
BAS |
27 |
Tracheobronchitis |
Sep 28 |
Y |
Epileptic seizures |
Piperacillin/tazobactam, linezolid |
61/M |
BAS |
27 |
Ventilator-associated pneumonia |
Oct 27 |
N |
Septic shock |
Piperacillin/tazobactam, linezolid, vancomycin, |
73/M | BAS | 15 | Ventilator-associated pneumonia | Dec 30 | N | COVID-19 | Piperacillin/tazobactam, linezolid, levofloxacin |
*BAS, bronchoaspiration; ICU, intensive care unit. †Isolation means that no other clinical pathology was reported by the responsible physician in the ICU. Therefore, E. miricola identification was considered as asymptomatic colonization. ‡Antibiograms were compatible with the same agent, but development of new resistances was identified during the 9-mo outbreak. Trimethoprim/sulfamethoxazole showed the best antibiogram sensitivity: 10 patients showed sensitivity, 4 intermediate sensitivity, and only 1 showed resistance. Sensitivity to levofloxacin was observed for 7 (46.7%) patients; 4 more showed intermediate sensitivity.